More on CYTR

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 51.87M
Marketable securities 50.6M
Proceeds from sale of RXi, received January 6, 2011
Receivable 1.6M
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable 57.39K
Prepaid expenses and other current assets 913.95K
Total current assets 105.04M
Equipment and furnishings, net 238.84K
Goodwill 183.78K
Other assets 121.9K
Total assets 105.58M
Current liabilities:
Accounts payable 3.8M
Accrued expenses and other current liabilities 6.75M
Warrant liabilities 11.95M
Total current liabilities 22.5M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 55.92K
Additional paid-in capital 373M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares) -2.53M
Accumulated deficit -287.44M
Total stockholders' equity 83.08M
Total liabilities and stockholders' equity 105.58M